Next Article in Journal
Effects of Pendrin Protein in Nasal Epithelial Cells on Mucin Production in the Context of Type 2 Inflammation
Next Article in Special Issue
Association Study of BDNF, SLC6A4, and FTO Genetic Variants with Schizophrenia Spectrum Disorders
Previous Article in Journal
Can Opioid-Free Anaesthesia Be Personalised? A Narrative Review
Previous Article in Special Issue
Depressive Pseudodementia with Reversible AD-like Brain Hypometabolism: A Case Report and a Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 13
Issue 3
10.3390/jpm13030501
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association of HTTLPR, BDNF, and FTO Genetic Variants with Completed Suicide in Slovakia

by
Aneta Bednarova
1,*,†,
Viera Habalova
2,†,
Silvia Farkasova Iannaccone
3,
Ivan Tkac
4,
Dominika Jarcuskova
5,
Michaela Krivosova
6,
Matteo Marcatili
7 and
Natasa Hlavacova
8
1
2nd Department of Psychiatry, Faculty of Medicine, Pavol Jozef Safarik University, University Hospital of Louis Pasteur, 041 90 Kosice, Slovakia
2
Department of Medical Biology, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Kosice, Slovakia
3
Department of Forensic Medicine, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Kosice, Slovakia
4
4th Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Safarik University, University Hospital of Louis Pasteur, 041 90 Kosice, Slovakia
5
1st Department of Psychiatry, Faculty of Medicine, Pavol Jozef Safarik University, University Hospital of Louis Pasteur, 040 11 Kosice, Slovakia
6
Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia
7
Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, 209 00 Monza, Italy
8
Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Pers. Med. 2023, 13(3), 501; https://doi.org/10.3390/jpm13030501
Submission received: 18 February 2023 / Revised: 7 March 2023 / Accepted: 8 March 2023 / Published: 10 March 2023
(This article belongs to the Special Issue Biomarkers in Psychiatric Disorders)
Browse Figure
Review Reports Versions Notes

Abstract

:
Since suicide and suicidal behavior are considered highly heritable phenotypes, the identification of genetic markers that can predict suicide risk is a clinically important topic. Several genes studied for possible associations between genetic polymorphisms and suicidal behaviors had mostly inconsistent and contradictory findings. The aim of this case-control study was to evaluate the associations between completed suicide and polymorphisms in genes BDNF (rs6265, rs962369), SLC6A4 (5-HTTLPR), and FTO (rs9939609) in relation to sex and BMI. We genotyped 119 completed suicide victims and 137 control subjects that were age, sex, and ethnicity matched. A significant association with completed suicide was found for BDNF rs962369. This variant could play a role in completed suicide, as individuals with the CC genotype were more often found among suicides than in control subjects. After sex stratification, the association remained significant only in males. A nominally significant association between the gene variant and BMI was observed for BDNF rs962369 under the overdominant model. Heterozygotes with the TC genotype showed a lower average BMI than homozygotes with TT or CC genotypes. FTO polymorphism (rs9939609) did not affect BMI in the group of Slovak suicide completers, but our findings follow an inverse association between BMI and completed suicide.

Graphical Abstract

1. Introduction

Suicide is the cause of more than 700,000 deaths every year [1]. Although the data from 2019 showed that the suicide mortality rate had a decreasing trend (from 19.65 to 10.50 per population of 100,000) in Europe between the years 2000–2019, the COVID-19 pandemic could have affected the current situation, and the most recent data are yet to come [2,3]. In Slovakia, the suicide mortality rate was lately reported to be 9.31 per 100,000 inhabitants, being higher with increasing age. The prevalence of completed suicide is almost seven-fold higher in Slovak men than women [4,5].
Suicidal behavior is characterized as suicide ideation, suicide planning and attempts, and suicide itself [6]. The contributing factors are categorized as distal (genetic predisposition, personality, early life trauma, neurobiological disturbances) and proximal, such as psychiatric disorder, physical disorder, and acute psychosocial crisis [7]. Indeed, suicide and suicidal behavior are considered highly heritable phenotypes [8,9]. However, the specific genes involved and underlying mechanisms together with the role of epigenetics are yet to be elucidated. So far, genetic association studies have discovered various candidate genes potentially involved in suicide susceptibility, and among the most studied have been genes affecting the serotoninergic system, other neurotransmitters from the monoaminergic system, or neurotrophic factors [10]. Since the discovery of brain-derived neurotrophic factor (BDNF), it has been widely studied in relation to various neuropsychiatric disorders [11]. The essential role of BDNF in neuronal growth, differentiation, maturation, and synaptic plasticity have led several research groups also to search for an association with suicidal behaviors by measuring its peripheral levels [12], BDNF gene expression, and epigenetic changes [13], but also the influence of BDNF polymorphisms [14]. A functional polymorphism of the BDNF gene, the Val66Met (rs6265) has been relatively widely investigated with regard to suicidal behavior; however, the findings are inconsistent. This single-nucleotide polymorphism (SNP) might increase the risk of suicidal behavior in certain ethnicities such as Caucasians and Asians, but not in the overall population [14]. Among other BDNF gene polymorphisms, rs962369 was found to have a strong association with suicidal ideation during antidepressant treatment [15] as well as with suicide completion [16]. We have previously demonstrated a significant association between BDNF (rs6265) and highly polygenic region 5-HTTLPR of the SLC6A4 (a gene-encoding serotonin transporter) genetic variations in patients suffering from affective disorders [17]. The latter genetic variant has also been studied with suicide. However, a recent meta-analysis did not confirm its association with suicidal behavior [18]. On the other hand, the authors found a significant association with the risk of violent suicide attempts. Another gene that is potentially involved in psychiatric disorders and suicide attempts could be the fat mass and obesity-associated gene (FTO), also known as alpha-ketoglutarate-dependent dioxygenase. Although the FTO gene was primarily found to be related to obesity and higher BMI (body mass index) risk [19], abundant expression of FTO in the brain [20] led to subsequent association studies with affective disorders [21,22] or completed suicide [23]. The important role of FTO in modulating brain functions was suggested by several studies in animal models [24,25,26]. Additionally, it was demonstrated that FTO is necessary for the correct function of the hippocampus by regulating BDNF processing [27].
The aim of this study was to evaluate the associations between completed suicide and polymorphisms in genes BDNF (rs6265, rs962369), SLC6A4 (5-HTTLPR), and FTO (rs9939609) in the Slovak population. We put extra attention on the evaluation of these polymorphisms in relation to the sex and BMI of the study subjects.

2. Materials and Methods

2.1. Study Sample

The current case-control study was performed in two groups of adult participants of Slovak origin (Caucasians). The case (suicide) group (n = 119) comprised individuals who committed suicide. In Slovakia, all deaths due to suicide or suspected suicide are referred to a coroner’s investigation and reported to the police. Suicide belongs to violent death, and it is necessary to order an autopsy according to legislation in Slovakia. Autopsies, including of suicides, were performed at the Medico-Legal and Pathological-Anatomical Department of the Health Care Surveillance Authority in Kosice (one of the seven departments in Slovakia). The control group (n = 137) was matched by age, sex, and ethnicity to the suicide group. The control group included adult volunteers with no relation to the cases, no known psychiatric disorders, and with no history of suicidal behavior. Blood samples from both groups were collected from November 2018 to November 2022, and the participation of control subjects in testing was voluntary and could be canceled by any individual at any time during the study. Classification of the subjects into the categories of underweight, normal weight, overweight, or obese was based on the cut-off values of BMI recommended for white populations [28]. This study was approved by the Ethics Committee of the University Hospital of Louis Pasteur in Kosice (149/2018/OPVaV), and control subjects provided written informed consent. The study was conducted in accordance with the Helsinki Declaration.

2.2. Genotyping

DNA from peripheral blood was extracted using the QIAamp DNA Blood Mini QIAcube Kit according to the manufacturer’s instructions on the QIAcube—robotic workstation for automated purification of DNA, RNA, or proteins (QIAGEN, Hilden, Germay). Genotyping of the FTO rs9939609, BDNF rs6265, and BDNF rs962369 was performed using asymmetric (primers ratio 1:10) real-time polymerase chain reaction and subsequent high-resolution melting analysis in the presence of an unlabeled probe on the Eco Real-Time PCR System (Illumina, Inc., San Diego, CA, USA). The reaction mixture contained 1× MeltDoctor™ HRM Master Mix (Applied Biosystems™, Waltham, MA, USA), appropriate oligonucleotides, and 20 ng of template DNA in a final volume of 15 μL. Genotypes were identified using EcoTM Software 4.1. The oligonucleotides were designed in our laboratory (Table 1). The 5-HTTLPR genetic variation was genotyped using forward 5′-GGCGTTGCCGCTCTGAATGC-3′ and reverse 5′-GAGGGACTGAGCTGGACAACCAC-3′ primers according to Murakami et al. [29]. The PCR products were separated by electrophoresis on a 2% agarose gel.

2.3. Statistical Analysis

The Hardy–Weinberg equilibrium (HWE) assumption was assessed for the tested groups by comparing the observed numbers of each genotype with those expected under the HWE for the estimated allele frequency. Online software SNPstats was used to assess the strength of the relative associations via odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) and p-value [30]. Codominant, dominant, overdominant, and recessive genetic models were used to analyze the association between genetic variations and phenotypes. Akaike’s Information Criteria (AIK) and Bayesian Information Criteria (BIC) were considered in model selection. Analysis of association was based on linear or logistic regression according to the response variable (quantitative or binary status (case-control), respectively). The Bonferroni correction was applied to correct for multiple testing. Because four polymorphisms were evaluated, a p-value of <0.0125 (a nominal value <0.05/4) was considered statistically significant.

3. Results

3.1. Characterization of the Subjects

A total of 256 subjects were included in the current study. Out of 119 suicides, 92 (77.3%) were males, and 27 (22.7%) were females (female: male ratio was 1:3.4). The mean age ± standard deviation (SD) of the suicide cases was 47.71 ± 17.57 years: 46.85 ± 16.65 in males and 50.63 ± 20.11 in females (Table 2). Obtained data showed seven categories of suicide methods. The most common suicide method was hanging or suffocation (71 persons, 59.66%), jumping (16 persons; 13.45%), and collision with a train (12 persons; 10.08%). The remaining suicide methods were categorized as shooting (9%), cutting (4%), and less than 2% frequency for electrocution or drug poisoning. Overall, 98% of cases completed suicide with the violent method. Suicide methods’ frequencies and BMI of suicide cases are shown in Table 3. Age-, gender-, and ethnicity-matched adults served as the control group. The mean age ± SD of the control group was 48.23 ± 18.85 years. Of 137 individuals, 107 (78.1%) were males, and 30 (21.9%) were females. The mean age was 47.36 ± 18.75 years in males and 51.33 ± 18.86 years in females (Table 2).
All collected blood samples were successfully genotyped for all genetic variations. The genotype distribution among controls and cases did not deviate from HWE (p ≥ 0.05) for all tested genetic variations.

3.2. Distribution of Genotypes of Selected Genetic Variants

As not all analyzed genetic models were statistically significant for 5-HTTLPR (ins/del), FTO (rs9939609), and BDNF (rs6265) variants, the distribution of genotypes and their possible association with completed suicide are presented under a codominant genetic model. In the case of the BDNF (rs962369), the results are also presented using a recessive model, since it achieved lower AIK and BIC scores than the co-dominant model (Table 4).
The distribution of 5-HTTLPR genotypes was similar between controls and cases (Table 4). There were no significant differences in male or female groups when evaluated separately. There was a trend for a higher frequency of the SS genotype in female suicide completers in comparison with the control female group (37% vs. 16.7%); however, the difference did not reach statistical significance.
No statistically significant association was found between FTO or BDNF (rs6265) and completed suicide under four studied genetic models nor after sex stratification (data are shown only for the codominant model in Table 4 and Table 5, respectively). We have, however, revealed a nominally significant increased risk of suicide in the subjects with the CC genotype in BDNF (rs962369) using a recessive model (CC vs. TT + TC OR = 3.39, 95% CI = 1.05–10.94, p = 0.03), irrespective of sex (Table 5). Having considered sex differences, a significant association between BDNF rs962369 and suicide was found only in males under the recessive model (CC vs. TT+TC; OR = 4.71, 95% CI = 1.27–17.43, p = 0.01). The results show that 12% of male suicide completers had the CC genotype, whereas in the female suicides, we did not find any individual with the CC genotype out of 27 suicide completers.

3.3. Association between HTTLPR, FTO, and BDNF Gene Variants and BMI in Suicide Completers

BMI values of 59.6% of suicide completers were within the normal range (18.5–25), 27.73% were overweight, 5% of subjects were underweight, and 7.6% were obese. The average BMI in all genotype categories ranged from 22.68–25.27 (Table 6). We assessed the association between four gene variants and the BMI of the suicide completers. A nominally significant association between the gene variant and BMI was observed for BDNF rs962369 under the overdominant model (p = 0.02). Heterozygotes with the TC genotype showed a lower average BMI of about 1.69 (95% C.I. −3.09–−0.29) than homozygotes with TT or CC genotypes. No statistically significant association between HTTLPR (ins/del), FTO rs9939609, or BDNF (rs6265) genotypes and BMI was found either in the codominant or in the dominant, recessive, or overdominant genetic models.

4. Discussion

Here, we present an association study of selected gene polymorphisms with suicide completion within the Slovak population. We investigated a serotonin system candidate, a functional polymorphism 5-HTTLPR (ins/del) in the SLC6A4 gene, two common polymorphisms in the widely studied neurotrophic factor gene BDNF (rs6265, rs962369), and finally, an FTO polymorphism (rs9939609). This is the first study exploring the risk of committing completed suicide in the Slovak population related to these selected variants. In our study, the female-to-male ratio in the case subjects was 1:3.4, which is in line with the sex discrepancy in suicide rates in Slovakia [4,5]. It is estimated that around 20% of global suicides are due to pesticide self-poisoning (nonviolent method), most of which occur in rural agricultural areas in low- and middle-income countries. Other common methods of suicide are hanging and firearms [1]. In our study, 98% of cases overall completed suicide with the violent method; the most frequent method (around 60%) was hanging or suffocation, a method with an increasing trend in many countries over the last 30 years [31,32].

4.1. Evaluation of an Association of BDNF Genetic Variants with Suicide

A promising candidate for an association with suicidal behavior is the BDNF gene. Two SNPs previously associated with suicidal behavior were analyzed in our study. The most studied BDNF polymorphism is rs6265 (Val66Met). In our study, we did not find significant differences in rs6265 under all analyzed genetic models, and no differences were found after gender stratification. Our results are in accordance with a meta-analysis study in which a significant association between BDNF rs6265 polymorphism and the risk of suicidal behavior in the overall population was not confirmed [14]. This meta-analysis included studies from three populations of Slavic origin (Croatia, Slovenia, and Poland), out of which three did not confirm any association [33,34,35], and one found a higher risk for carriers of at least one minor allele (Met-Met or Val-Met) but only in female suicide victims [36]. Neither the more recent study from Central Europe [37] nor an earlier European multicenter study [38] has found an association between rs6365 and suicidal behavior.
Although this broadly studied missense variant of BDNF did not show significant results, another polymorphism, rs962369, could be another candidate for predicting increased suicide risk. In our study, out of four observed polymorphisms, the only association with completed suicide was found for BDNF rs962369. The association with BDNF rs962369 and susceptibility to suicide has been significant after gender stratification in males under recessive models. On the contrary, in the recent Slovenian study, none of the seven BDNF polymorphisms showed an association with completed suicide when used as a single marker. However, haplotype analysis of five selected polymorphisms showed that in such a combination, major allele T of rs962369 contributed to a higher suicide risk association [16]. Out of 123 polymorphisms in the GENDEP project, the strongest association with suicidal ideation was observed in rs962369 genetic variants [15]. Although the study assessed only suicidal ideation during antidepressant treatment, the outcomes correspond with our observation. Studies on animal models show the tendency of developing BDNF-deficient-related diseases such as depression or anxiety is higher in female animals [39], and that sex hormones or steroids can modulate the activities of BDNF, which may account for its functional discrepancy in different sexes [40,41]. Although the number of female cases and controls in our study was too low to make any conclusions, we speculate that the BDNF rs962369 variant could act in a sex-dependent manner.

4.2. Evaluation of an Association of 5-HTTLPR (ins/del) Genetic Variants with Suicide

One of the most studied genetic variations associated with suicide behavior is a highly polymorphic region 5-HTTLPR (ins/del) of the SLC6A4 gene-encoding serotonin transporter. So far, controversial results have been obtained. Out of systematic reviews and meta-analyses, some studies confirmed the higher susceptibility of short allele (S) carriers for suicidal behavior [42,43,44], but others have not [18,45], or contradictory results have been found in which a positive association was found with long allele (L) carriers [46]. Interestingly, discrepancies have also been found when distinct phenotypes such as suicidal behavior generally, suicidal ideation, history of suicide attempts, or a complete suicide only are considered. The 5-HTTLPR polymorphism has been found to be significantly associated with suicide attempts, but not with completed suicides [42,45]. Other meta-analyses did not confirm the association of the S allele and suicidal behavior generally; however, they found an association of the S allele with suicide attempts within the same psychiatric diagnosis, also with violent suicide [47] or violent suicide attempt [18].
In the present study, we did not reveal any significant difference between genetic variations of the 5-HTT gene promoter comparing suicide cases and controls. The result follows the studies performed in other Central Europe populations [48,49] and within individuals of Slavic origin [50,51,52]. Interestingly, a huge study that involved more than 100,000 subjects from 38 countries investigating an association between allelic frequencies in various countries and their suicide rates found that the S allele acts as a protective factor in Caucasians, whereas it acts as a risk factor in non-Caucasian populations [53]. We also evaluated HTTLPR genetic variants after gender stratification, as some studies found an association only in males [54] and others only in females [55]. Our results did not show either of these associations, although there was a trend for a higher frequency of the SS genotype in female suicide completers.

4.3. The FTO Genetic Variant (rs9939609) in the Context of Suicide and BMI

Within the genes related to obesity, the FTO gene has one of the strongest links with this condition in the human population. In the most studied polymorphism of this gene, rs9939609, minor allele A was found to positively affect obesity and BMI [19,56]. The FTO gene has recently been studied in association with affective disorders given its high abundance in the brain and often comorbid obesity and depression. A bidirectional relationship between obesity and higher BMI with depression has been proposed lately [57], although the underlying mechanisms have not yet been elucidated [58]. Up to 12% of a shared genetic component was found between depression and obesity [59]. However, there are various phenotypes within depressive disorder, and though one type is characterized by hyperphagia, another can lead to weight loss [60]. The meta-analysis by Rivera et al. [61] supported a significant interaction between FTO, depression, and BMI, indicating that depression increases the effect of FTO on BMI; depressed subjects had an additional effect of FTO on BMI that corresponded to a BMI increase of 2.2% for each A allele. The mentioned meta-analysis did not confirm an association between the rs9939609 A risk allele and depression, similar to that in the earlier studies [21,22]. Considering the association studies between this polymorphism and suicide, an inverse association between the A allele and complete suicide was reported in the Polish population, suggesting a codominant effect of the risk allele [23]. One study has suggested that the A allele could be a protective variant for depression development [62].
We aimed to test the correlation between the BMI and FTO rs9939609 genotypes in a group of suicide completers. In our study, we did not reveal any significant association between FTO gene polymorphism and BMI in suicide completers, even after gender stratification.
This study has limitations such as its relatively small number of cases and controls, particularly in the female groups. However, this corresponds with the discrepancy in suicide rate frequency in women and men in the Slovak population. The study’s strength is that the control subjects were cautiously matched by age, gender, and ethnicity to their suicide counterparts. Another strength is that this is the first Slovak association study of variants 5-HTTLPR (ins/del) in the SLC6A4 gene, BDNF (rs6265, rs962369), and FTO (rs9939609) with completed suicide. Our main result is that the BDNF rs962369 variant could play a role in completed suicide, as individuals with the CC genotype were more often found among suicides than in control subjects. The finding was confirmed mainly for male individuals. In the female group, the result cannot be interpreted unequivocally due to the small number of cases and controls. Another important finding of this study is that FTO polymorphism (rs9939609) did not affect BMI in the group of Slovak suicide completers, but our findings follow an inverse association between BMI and completed suicide.

5. Conclusions

The results of this study suggest that rs962369 polymorphism of the BDNF gene could potentially be involved in the higher risk of committing complete suicide in the Slovak male population. We did not find any association between other evaluated genetic variants, but studies with more included subjects are needed to verify this finding. Interestingly, FTO genetic variants did not affect the BMI of Slovak suicide completers.

Author Contributions

Conceptualization, A.B.; methodology, A.B. and V.H.; software, V.H.; validation, I.T.; genotyping, V.H.; formal analysis, N.H.; investigation, A.B., V.H. and S.F.I.; resources, A.B. and. I.T.; data curation, A.B. and S.F.I.; writing—original draft preparation, A.B., D.J., M.K. and M.M.; writing—review and editing, A.B., V.H., I.T. and N.H.; visualization, M.K.; supervision, I.T.; project administration, A.B.; funding acquisition, A.B. and I.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Health of the Slovak Republic (no. MZ2019/29-UPJS1) and VEGA 1/0183/20.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University Hospital of Luis Pasteur, Kosice, Slovakia (149/2018/OPVaV).

Informed Consent Statement

Control subjects provided written informed consent.

Data Availability Statement

The data that supports the findings of this study are available upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. WHO. Suicide. Available online: https://www.who.int/news-room/fact-sheets/detail/suicide (accessed on 30 October 2022).
  2. Pathirathna, M.L.; Nandasena, H.M.R.K.G.; Atapattu, A.M.M.P.; Weerasekara, I. Impact of the COVID-19 Pandemic on Suicidal Attempts and Death Rates: A Systematic Review. BMC Psychiatry 2022, 22, 1–15. [Google Scholar] [CrossRef]
  3. Farooq, S.; Tunmore, J.; Ali, W.; Ayub, M. Suicide, Self-Harm and Suicidal Ideation during COVID-19: A Systematic Review. Psychiatry Res. 2021, 306, 114228. [Google Scholar] [CrossRef] [PubMed]
  4. WHO. Suicide Rates. Available online: https://www.who.int/data/gho/data/themes/mental-health/suicide-rates (accessed on 30 October 2022).
  5. Brazinova, A.; Moravansky, N.; Gulis, G.; Skodacek, I. Suicide Rate Trends in the Slovak Republic in 1993–2015. Int. J. Soc. Psychiatry 2017, 63, 161–168. [Google Scholar] [CrossRef] [PubMed]
  6. WHO. Preventing Suicide: A Global Imperative. 2014; pp. 1–89. Available online: https://www.who.int/publications/i/item/9789241564779 (accessed on 7 March 2023).
  7. Hawton, K.; van Heeringen, K. Suicide. Lancet 2009, 373, 1372–1381. [Google Scholar] [CrossRef]
  8. Diblasi, E.; Kang, J.; Docherty, A.R. Genetic Contributions to Suicidal Thoughts and Behaviors. Psychol. Med. 2021, 51, 2148–2155. [Google Scholar] [CrossRef]
  9. Brent, D.A.; Mann, J.J. Family Genetic Studies, Suicide, and Suicidal Behavior. Am. J. Med. Genet. C Semin. Med. Genet. 2005, 133C, 13–24. [Google Scholar] [CrossRef]
  10. Mirkovic, B.; Laurent, C.; Podlipski, M.A.; Frebourg, T.; Cohen, D.; Gerardin, P. Genetic Association Studies of Suicidal Behavior: A Review of the Past 10 Years, Progress, Limitations, and Future Directions. Front. Psychiatry 2016, 7, 1. [Google Scholar] [CrossRef] [Green Version]
  11. Schenkel, L.C.; Segal, J.; Becker, J.A.; Manfro, G.G.; Bianchin, M.M.; Leistner-Segal, S. The BDNF Val66Met Polymorphism Is an Independent Risk Factor for High Lethality in Suicide Attempts of Depressed Patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 940–944. [Google Scholar] [CrossRef]
  12. Fusar-Poli, L.; Aguglia, A.; Amerio, A.; Orsolini, L.; Salvi, V.; Serafini, G.; Volpe, U.; Amore, M.; Aguglia, E. Peripheral BDNF Levels in Psychiatric Patients with and without a History of Suicide Attempt: A Systematic Review and Meta-Analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2021, 111, 110342. [Google Scholar] [CrossRef]
  13. Ropret, S.; Kouter, K.; Zupanc, T.; Paska, A.V. BDNF Methylation and MRNA Expression in Brain and Blood of Completed Suicides in Slovenia. World J. Psychiatry 2021, 11, 1301. [Google Scholar] [CrossRef]
  14. González-Castro, T.B.; Salas-Magaña, M.; Juárez-Rojop, I.E.; López-Narváez, M.L.; Tovilla-Zárate, C.A.; Hernández-Díaz, Y. Exploring the Association between BDNF Val66Met Polymorphism and Suicidal Behavior: Meta-Analysis and Systematic Review. J. Psychiatr Res. 2017, 94, 208–217. [Google Scholar] [CrossRef] [PubMed]
  15. Perroud, N.; Aitchison, K.J.; Uher, R.; Smith, R.; Huezo-Diaz, P.; Marusic, A.; Maier, W.; Mors, O.; Placentino, A.; Henigsberg, N.; et al. Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology 2009, 34, 2517–2528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Ropret, S.; Zupanc, T.; Komel, R.; Videtič Paska, A. Single Nucleotide Polymorphisms in the BDNF Gene and Suicide in the Slovenian Sample. Neurosci. Lett. 2015, 602, 12–16. [Google Scholar] [CrossRef] [PubMed]
  17. Bednarova, A.; Cizmarikova, M.; Habalova, V.; Jarcuskova, D. Evaluation of 5-HTTLPR (Insertion/Deletion) and BDNF (Rs6265) Genetic Variations in the Slovakian Individuals Suffering from Affective Disorders. Gen. Physiol. Biophys. 2021, 40, 365–376. [Google Scholar] [CrossRef]
  18. Fanelli, G.; Serretti, A. The Influence of the Serotonin Transporter Gene 5-HTTLPR Polymorphism on Suicidal Behaviors: A Meta-Analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2019, 88, 375–387. [Google Scholar] [CrossRef]
  19. Frayling, T.M.; Timpson, N.J.; Weedon, M.N.; Zeggini, E.; Freathy, R.M.; Lindgren, C.M.; Perry, J.R.B.; Elliott, K.S.; Lango, H.; Rayner, N.W.; et al. A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity. Science 2007, 316, 889. [Google Scholar] [CrossRef] [Green Version]
  20. Dina, C.; Meyre, D.; Gallina, S.; Durand, E.; Körner, A.; Jacobson, P.; Carlsson, L.M.S.; Kiess, W.; Vatin, V.; Lecoeur, C.; et al. Variation in FTO Contributes to Childhood Obesity and Severe Adult Obesity. Nat. Genet. 2007, 39, 724–726. [Google Scholar] [CrossRef]
  21. Yao, Y.; Wen, Y.; Du, T.; Sun, N.; Deng, H.; Ryan, J.; Rao, S. Meta-Analysis Indicates That SNP Rs9939609 within FTO Is Not Associated with Major Depressive Disorder (MDD) in Asian Population. J. Affect. Disord. 2016, 193, 27–30. [Google Scholar] [CrossRef]
  22. Du, T.; Rao, S.; Wu, L.; Ye, N.; Liu, Z.; Hu, H.; Xiu, J.; Shen, Y.; Xu, Q. An Association Study of the M6A Genes with Major Depressive Disorder in Chinese Han Population. Artic. J. Affect. Disord. 2015, 183, 279–286. [Google Scholar] [CrossRef]
  23. Chojnicka, I.; Fudalej, S.; Walczak, A.; Wasilewska, K.; Fudalej, M.; Stawinski, P.; Strawa, K.; Pawlak, A.; Wojnar, M.; Krajewski, P.; et al. Inverse Association between Obesity Predisposing FTO Genotype and Completed Suicide. PLoS ONE 2014, 9, e108900. [Google Scholar] [CrossRef]
  24. Li, L.; Zang, L.; Zhang, F.; Chen, J.; Shen, H.; Shu, L.; Liang, F.; Feng, C.; Chen, D.; Tao, H.; et al. Fat Mass and Obesity-Associated (FTO) Protein Regulates Adult Neurogenesis. Hum. Mol. Genet. 2017, 26, 2398–2411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Hess, M.E.; Hess, S.; Meyer, K.D.; Verhagen, L.A.W.; Koch, L.; Brönneke, H.S.; Dietrich, M.O.; Jordan, S.D.; Saletore, Y.; Elemento, O.; et al. The Fat Mass and Obesity Associated Gene (Fto) Regulates Activity of the Dopaminergic Midbrain Circuitry. Nat. Neurosci. 2013, 16, 1042–1048. [Google Scholar] [CrossRef] [PubMed]
  26. Widagdo, J.; Zhao, Q.Y.; Kempen, M.J.; Tan, M.C.; Ratnu, V.S.; Wei, W.; Leighton, L.; Spadaro, P.A.; Edson, J.; Anggono, V.; et al. Experience-Dependent Accumulation of N6-Methyladenosine in the Prefrontal Cortex Is Associated with Memory Processes in Mice. J. Neurosci. 2016, 36, 6771. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Spychala, A.; Rüther, U. FTO Affects Hippocampal Function by Regulation of BDNF Processing. PLoS ONE 2019, 14, e0211937. [Google Scholar] [CrossRef] [PubMed]
  28. Weir, C.B.; Jan, A. BMI Classification Percentile and Cut Off Points; StatPearls Publishing: St. Petersburg, FL, USA, 2022. [Google Scholar]
  29. Murakami, F.; Shimomura, T.; Kotani, K.; Ikawa, S.; Nanba, E.; Adachi, K. Anxiety Traits Associated with a Polymorphism in the Serotonin Transporter Gene Regulatory Region in the Japanese. J. Hum. Genet. 1999, 44, 15–17. [Google Scholar] [CrossRef] [PubMed]
  30. Solé, X.; Guinó, E.; Valls, J.; Iniesta, R.; Moreno, V. SNPStats: A Web Tool for the Analysis of Association Studies. Bioinformatics 2006, 22, 1928–1929. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Sabrinskas, R.; Hamilton, B.; Daniel, C.; Oliffe, J. Suicide by Hanging: A Scoping Review. Int. J. Ment. Health Nurs. 2022, 31, 278–294. [Google Scholar] [CrossRef]
  32. Gunnell, D.; Bennewith, O.; Hawton, K.; Simkin, S.; Kapur, N. The Epidemiology and Prevention of Suicide by Hanging: A Systematic Review. Int. J. Epidemiol. 2005, 34, 433–442. [Google Scholar] [CrossRef] [Green Version]
  33. Chojnicka, I.; Strawa, K.; Fudalej, S.; Fudalej, M.; Pawlak, A.; Kostrzewa, G.; Wojnar, M.; Krajewski, P.; Poski, R. Analysis of Four Genes Involved in the Neurodevelopment Shows Association of Rs4307059 Polymorphism in the Cadherin 9/10 Region with Completed Suicide. Neuropsychobiology 2012, 66, 134–140. [Google Scholar] [CrossRef]
  34. Nedic, G.; Nikolac Perkovic, M.; Nenadic Sviglin, K.; Muck-Seler, D.; Borovecki, F.; Pivac, N. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Alcohol-Related Phenotypes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 40, 193–198. [Google Scholar] [CrossRef]
  35. Zarrilli, F.; Angiolillo, A.; Castaldo, G.; Chiariotti, L.; Keller, S.; Sacchetti, S.; Marusic, A.; Zagar, T.; Carli, V.; Roy, A.; et al. Brain Derived Neurotrophic Factor (BDNF) Genetic Polymorphism (Val66Met) in Suicide: A Study of 512 Cases. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2009, 150B, 599–600. [Google Scholar] [CrossRef] [PubMed]
  36. Pregelj, P.; Nedic, G.; Paska, A.V.; Zupanc, T.; Nikolac, M.; Balažic, J.; Tomori, M.; Komel, R.; Seler, D.M.; Pivac, N. The Association between Brain-Derived Neurotrophic Factor Polymorphism (BDNF Val66Met) and Suicide. J. Affect. Disord. 2011, 128, 287–290. [Google Scholar] [CrossRef] [PubMed]
  37. Berent, D.; Szymańska, B.; Kulczycka-Wojdala, D.; Macander, M.; Pawłowska, Z.; Wojnar, M. The Role of Childhood Adversities, FKBP5, BDNF, NRN1, and Generalized Self-Efficacy in Suicide Attempts in Alcohol-Dependent Patients. Pharmacol. Rep. 2020, 72, 730. [Google Scholar] [CrossRef] [PubMed]
  38. Schosser, A.; Carlberg, L.; Calati, R.; Serretti, A.; Massat, I.; Spindelegger, C.; Linotte, S.; Mendlewicz, J.; Souery, D.; Zohar, J.; et al. The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. Int. J. Neuropsychopharmacol. 2017, 20, 782. [Google Scholar] [CrossRef] [Green Version]
  39. Monteggia, L.M.; Luikart, B.; Barrot, M.; Theobold, D.; Malkovska, I.; Nef, S.; Parada, L.F.; Nestler, E.J. Brain-Derived Neurotrophic Factor Conditional Knockouts Show Gender Differences in Depression-Related Behaviors. Biol. Psychiatry 2007, 61, 187–197. [Google Scholar] [CrossRef]
  40. Fanaei, H.; Karimian, S.M.; Sadeghipour, H.R.; Hassanzade, G.; Kasaeian, A.; Attari, F.; Khayat, S.; Ramezani, V.; Javadimehr, M. Testosterone Enhances Functional Recovery after Stroke through Promotion of Antioxidant Defenses, BDNF Levels and Neurogenesis in Male Rats. Brain Res. 2014, 1558, 74–83. [Google Scholar] [CrossRef]
  41. Li, M.; Masugi-Tokita, M.; Takanami, K.; Yamada, S.; Kawata, M. Testosterone Has Sublayer-Specific Effects on Dendritic Spine Maturation Mediated by BDNF and PSD-95 in Pyramidal Neurons in the Hippocampus CA1 Area. Brain Res. 2012, 1484, 76–84. [Google Scholar] [CrossRef] [PubMed]
  42. Anguelova, M.; Benkelfat, C.; Turecki, G. A Systematic Review of Association Studies Investigating Genes Coding for Serotonin Receptors and the Serotonin Transporter: II. Suicidal Behavior. Mol. Psychiatry 2003, 8, 646–653. [Google Scholar] [CrossRef] [Green Version]
  43. Li, D.; He, L. Meta-Analysis Supports Association between Serotonin Transporter (5-HTT) and Suicidal Behavior. Mol. Psychiatry 2007, 12, 47–54. [Google Scholar] [CrossRef] [Green Version]
  44. Schild, A.H.E.; Pietschnig, J.; Tran, U.S.; Voracek, M. Genetic Association Studies between SNPs and Suicidal Behavior: A Meta-Analytical Field Synopsis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46, 36–42. [Google Scholar] [CrossRef]
  45. Clayden, R.C.; Zaruk, A.; Meyre, D.; Thabane, L.; Samaan, Z. The Association of Attempted Suicide with Genetic Variants in the SLC6A4 and TPH Genes Depends on the Definition of Suicidal Behavior: A Systematic Review and Meta-Analysis. Transl. Psychiatry 2012, 2, e166. [Google Scholar] [CrossRef] [Green Version]
  46. De Medeiros Alves, V.; Bezerra, D.; de Andrade, T.; de Melo Neto, V.; Nardi, A. Genetic Polymorphisms Might Predict Suicide Attempts in Mental Disorder Patients: A Systematic Review and Meta-Analysis. CNS Neurol. Disord. Drug Targets 2015, 14, 820–827. [Google Scholar] [CrossRef] [PubMed]
  47. Lin, P.Y.; Tsai, G. Association between Serotonin Transporter Gene Promoter Polymorphism and Suicide: Results of a Meta-Analysis. Biol. Psychiatry 2004, 55, 1023–1030. [Google Scholar] [CrossRef] [PubMed]
  48. Bokor, J.; Gonda, X.; Dome, P.; Faludi, G.; Dinya, E.; Laszik, A. Association between the 5-HTTLPR Polymorphism of the Serotonin Transporter Gene and Suicide: A Case-Control Pilot Study. Neuropsychopharmacol. Hung. 2017, 19, 5–10. [Google Scholar] [PubMed]
  49. Pawlak, J.; Dmitrzak-Weglarz, M.; Wilkosc, M.; Szczepankiewicz, A.; Leszczynska-Rodziewicz, A.; Zaremba, D.; Kapelski, P.; Rajewska-Rager, A.; Hauser, J. Suicide Behavior as a Quantitative Trait and Its Genetic Background. J. Affect. Disord. 2016, 206, 241–250. [Google Scholar] [CrossRef]
  50. Božina, N.; Jovanović, N.; Podlesek, A.; Rojnić Kuzman, M.; Kudumija Slijepčević, M.; Roguljić, A.; Dimitrović, A.; Božina, T.; Lovrić, J.; Ljubić, H.; et al. Suicide Ideators and Attempters with Schizophrenia—The Role of 5-HTTLPR, Rs25531, and 5-HTT VNTR Intron 2 Variants. J. Psychiatr. Res. 2012, 46, 767–773. [Google Scholar] [CrossRef] [Green Version]
  51. Hranilovic, D.; Stefulj, J.; Furac, I.; Kubat, M.; Balija, M.; Jernej, B. Serotonin Transporter Gene Promoter (5-HTTLPR) and Intron 2 (VNTR) Polymorphisms in Croatian Suicide Victims. Biol. Psychiatry 2003, 54, 884–889. [Google Scholar] [CrossRef]
  52. Pungercic, G.; Videtic, A.; Pestotnik, A.; Pajnic, I.Z.; Zupanc, T.; Balazic, J.; Tomori, M.; Komel, R. Serotonin Transporter Gene Promoter (5-HTTLPR) and Intron 2 (VNTR) Polymorphisms: A Study on Slovenian Population of Suicide Victims. Psychiatr. Genet. 2006, 16, 187–191. [Google Scholar] [CrossRef]
  53. Schild, A.H.E.; Nader, I.W.; Pietschnig, J.; Voracek, M. Ethnicity Moderates the Association Between 5-HTTLPR and National Suicide Rates. Arch. Suicide Res. 2014, 18, 1–13. [Google Scholar] [CrossRef]
  54. Limosin, F.; Loze, J.Y.; Boni, C.; Hamon, M.; Adès, J.; Rouillon, F.; Gorwood, P. Male-Specific Association between the 5-HTTLPR S Allele and Suicide Attempts in Alcohol-Dependent Subjects. J. Psychiatr. Res. 2005, 39, 179–182. [Google Scholar] [CrossRef]
  55. Gaysina, D.; Zainullina, A.; Gabdulhakov, R.; Khusnutdinova, E. The Serotonin Transporter Gene: Polymorphism and Haplotype Analysis in Russian Suicide Attempters. Neuropsychobiology 2006, 54, 70–74. [Google Scholar] [CrossRef] [PubMed]
  56. Scuteri, A.; Sanna, S.; Chen, W.M.; Uda, M.; Albai, G.; Strait, J.; Najjar, S.; Nagaraja, R.; Orrú, M.; Usala, G.; et al. Genome-Wide Association Scan Shows Genetic Variants in the FTO Gene Are Associated with Obesity-Related Traits. PLoS Genet. 2007, 3, 1200–1210. [Google Scholar] [CrossRef] [PubMed]
  57. Luppino, F.S.; de Wit, L.M.; Bouvy, P.F.; Stijnen, T.; Cuijpers, P.; Penninx, B.W.J.H.; Zitman, F.G. Overweight, Obesity, and Depression: A Systematic Review and Meta-Analysis of Longitudinal Studies. Arch. Gen. Psychiatry 2010, 67, 220–229. [Google Scholar] [CrossRef] [PubMed]
  58. Zarza-Rebollo, J.A.; Molina, E.; Rivera, M. The Role of the FTO Gene in the Relationship between Depression and Obesity. A Systematic Review. Neurosci. Biobehav. Rev. 2021, 127, 630–637. [Google Scholar] [CrossRef]
  59. Wray, N.R.; Ripke, S.; Mattheisen, M.; Trzaskowski, M.; Byrne, E.M.; Abdellaoui, A.; Adams, M.J.; Agerbo, E.; Air, T.M.; Andlauer, T.M.F.; et al. Genome-Wide Association Analyses Identify 44 Risk Variants and Refine the Genetic Architecture of Major Depression. Nat. Genet. 2018, 50, 668–681. [Google Scholar] [CrossRef] [Green Version]
  60. Milaneschi, Y.; Lamers, F.; Berk, M.; Penninx, B.W.J.H. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. Biol. Psychiatry 2020, 88, 369–380. [Google Scholar] [CrossRef]
  61. Rivera, M.; Locke, A.E.; Corre, T.; Czamara, D.; Wolf, C.; Ching-Lopez, A.; Milaneschi, Y.; Kloiber, S.; Cohen-Woods, S.; Rucker, J.; et al. Interaction between the FTO Gene, Body Mass Index and Depression: Meta-Analysis of 13701 Individuals. Br. J. Psychiatry 2017, 211, 70–76. [Google Scholar] [CrossRef] [Green Version]
  62. Samaan, Z.; Anand, S.; Zhang, X.; Desai, D.; Rivera, M.; Pare, G.; Thabane, L.; Xie, C.; Gerstein, H.; Engert, J.C.; et al. The Protective Effect of the Obesity-Associated Rs9939609 A Variant in Fat Mass- and Obesity-Associated Gene on Depression. Mol. Psychiatry 2013, 18, 1281–1286. [Google Scholar] [CrossRef]
Table
Table 1. Sequences of oligonucleotides.
Table 1. Sequences of oligonucleotides.
GeneOligonucleotidesSequences
FTO rs9939609forward-limit5′-GCATTTAGAATGTCTGAATTATTATTCTAG-3′
reverse-excess5′-CCTATTAAAACTTTAGAGTAACAGAG-3′
probe5′-TGCTGTGAATTTTGTGATGCACTTGGAT-Phos′
BDNF rs6265forward-limit5′-GCCGAACTTTCTGGTCCTCATCC-3′
reverse-excess5′-AAGGCAGGTTCAAGAGGCTTG-3
probe5′-GCTCTTCTATCACGTGTTCGAAAGTGTC-Phos
BDNF rs962369forward-limit5′-GACATTTTTATGAGAAGGGTTTACATAAG-3′
reverse-excess5′-AAAGAATTGCTCACTGTAATGAC-3′
probe5′-TGCCAAGAGAGTTGAGTCCATGG-Phos
Table
Table 2. Age characteristics of control and suicide group of the subjects.
Table 2. Age characteristics of control and suicide group of the subjects.
AgeControlSuicides
Total
(n = 137)		Males
(n = 107)		Females
(n = 30)		Total
(n = 119)		Males
(n = 92)		Females
(n = 27)
average ± SD48.23 ± 18.8547.36 ± 18.7551.33 ± 18.8647.71 ± 17.5746.86 ± 16.6550.63 ± 20.11
median474552.54846.551
min–max18–9121–9018–9114–9014–8515–90
<35 years40 (29.20%)34 (31.78%)6 (20.00%)31 (26.05%)26 (28.26%)5 (18.52%)
35–49 years30 (21.90%)25 (23.36%)5 (16.67%)35 (29.41%)29 (31.52%)6 (22.22%)
>50 years67 (48.91%)48 (44.86%)19 (63.33%)53 (44.54%)37 (40.22%)16 (59.26%)
Data are expressed as mean ± standard deviation (SD)/min/max/%.
Table
Table 3. Methods of suicide and BMI in suicide completers.
Table 3. Methods of suicide and BMI in suicide completers.
Total Males Females
Method of Suiciden%n%n%
hanging or suffocation7159.6%5861.1%1348.2%
jumping from high places1613.4%99.47%725.9%
collision with a train1210.1%77.37%518.5%
shooting119.24%1111.6%00.00%
cutting54.20%55.26%00.00%
electrocution21.68%22.11%00.00%
poisoning21.68%00.00%27.41%
BMI
average ± SD24.22 ± 3.83 24.17 ± 3.30 24.42 ± 5.35
median 23.84 23.86 23.53
min–max13.6–35.7 13.9–33.31 13.67–35.7
BMI < 18.5 (underweight)6 5.04%33.26%311.1%
BMI = 18.5–24.9 (normal)7159.6%6166.3%1037.4%
BMI = 25–29.9 (overweight)327.7%2223.9%1140.7%
BMI > 30 (obese)97.56%66.52%311.1%
Table
Table 4. Distribution of genotypes and analysis of the association between 5-HTTLPR (ins/del) and FTO (rs9939609) gene variants and suicide risk.
Table 4. Distribution of genotypes and analysis of the association between 5-HTTLPR (ins/del) and FTO (rs9939609) gene variants and suicide risk.
SubjectsGenotype/AlleleControl
n (%)		Suicides
n (%)		Odds Ratio
(95% CI)		p-ValueHWE
Controls
5-HTTLPR (ins/del)
Codominant model
TotalLL32 (23.4%)19 (16.0%)1.000.320.94
LS68 (49.6%)63 (52.9%)1.56 (0.80–3.03)
SS37 (27.0%)37 (31.1%)1.68 (0.81–3.49)
Allele, S
(proportion)		142 (0.52)137 (0.58)
MalesLL25 (23.4%)17 (18.5%)1.000.650.53
LS50 (46.7%)48 (52.2%)1.41 (0.68–2.94)
SS32 (29.9%)27 (29.4%)1.24 (0.56–2.77)
Allele, S
(proportion)		114 (0.53)102 (0.55)
FemalesLL7 (23.3%)2 (7.4%)1.000.090.26
LS18 (60.0%)15 (55.6%)2.92 (0.53–16.19)
SS5 (16.7%)10 (37.0%)7.00 (1.04–46.94)
Allele, S
(proportion)		28 (0.47)35 (0.65)
FTO (rs9939609)
Codominant model
TotalTT42 (30.7%)46 (38.7%)1.000.400.61
TA65 (47.5%)49 (41.2%)0.69 (0.39–1.20)
AA30 (21.9%)24 (20.2%)0.73 (0.37–1.44)
Allele, A
(proportion)		125 (0.46)97 (0.41)
MalesTT34 (31.8%)36 (39.1%)1.000.550.89
TA52 (48.6%)39 (42.4%)0.71 (0.38–1.32)
AA21 (19.6%)17 (18.5%)0.76 (0.35–1.69)
Allele, A
(proportion)		94 (0.44)73 (0.40)
FemalesTT8 (26.7%)10 (37.0%)1.000.700.47
TA13 (43.3%)10 (37.0%)0.62 (0.18–2.13)
AA9 (30%)7 (26.0%)0.62 (0.16–2.42)
Allele, A
(proportion)		31 (0.52)24 (0.44)
Table
Table 5. Distribution of genotypes and analysis of the association between BDNF (rs6265) and BDNF (rs962369) gene variants and suicide risk.
Table 5. Distribution of genotypes and analysis of the association between BDNF (rs6265) and BDNF (rs962369) gene variants and suicide risk.
SubjectsGenotype/AlleleControl
n (%)		Suicides
n (%)		Odds Ratio
(95% CI)		p-ValueHWE
Controls
BDNF (rs6265)
Codominant model
TotalCC92 (67.2%)82 (68.9%)1.000.920.82
CT41 (29.9%)33 (27.7%)0.90 (0.52–1.56)
TT4 (2.9%)4 (3.4%)1.12 (0.27–4.63)
Allele, T
(proportion)		49 (18%)41 (17%)
MalesCC75 (70.1%)63 (68.5%)1.000.840.92
CT29 (27.1%)25 (27.2%)1.03 (0.55–1.93)
TT3 (2.8%)4 (4.3%)1.59 (0.34–7.36)
Allele, T
(proportion)		35 (0.16)33 (0.18)
FemalesCC17 (56.7%)19 (70.4%)1.000.340.52
CT12 (40.0%)8 (29.6%)0.60 (0.20–1.81)
TT1 (3.3%)0 (0.0%)0.00 (0.00–NA)
Allele, T
(proportion)		14 (0.23)8 (0.15)
BDNF (rs962369)
Codominant model
TotalTT81 (59.1%)67 (56.3%)1.000.090.20
TC52 (38.0%)41 (34.5%)0.95 (0.56–1.60)
CC4 (2.9%)11 (9.2%)3.32 (1.01–10.92)
Allele, C
(proportion)		60 (0.22)63 (0.26)
MalesTT65 (60.8%)51 (55.4%)1.000.04
TC39 (36.5%)30 (32.6%)0.98 (0.54–1.79)
CC3 (2.8%)11 (12.0%)4.67 (1.24–17.64)
Allele, C
(proportion)		97 (0.24)45 (0.21)52 (0.28)
FemalesTT16 (53.3%)16 (59.3%)1.000.500.39
TC13 (43.3%)11 (40.7%)0.85 (0.29–2.44)
CC1 (3.3%)0 (0.0%)0.00 (0.00-NA)
Allele, C
(proportion)		15 (0.25)11 (0.2)
Recessive model
TotalTT+TC133 (97.1%)108 (90.8%)1.000.03
CC4 (2.9%)11 (9.2%)3.39 (1.05–10.94)
MalesTT+TC104 (97.2%)81 (88.0%)1.000.01
CC3 (2.8%)11 (12.0%)4.71 (1.27–17.43)
Table
Table 6. Analysis of the association between four gene variants and BMI in suicide cases.
Table 6. Analysis of the association between four gene variants and BMI in suicide cases.
GeneModelGenderGenotypeBMI
mean (s.e.)		Difference
(95% CI)		p-Value
HTTLPR
ins/delCodominantTotalLL23.93 (0.67)ref.0.90
LS24.28 (0.47)0.35 (−1.20–1.90)
SS24.05 (0.82)0.12 (−1.99–2.24)
MaleLL24.10 (0.50)ref.1.00
LS24.03 (0.51)−0.07 (−1.64–1.50)
SS24.06 (0.90)−0.04 (−2.06–1.98)
FemaleLL23.47 (2.14)ref.0.76
LS25.08 (1.13)1.61 (−2.68–5.90)
SS23.96 (2.16)0.49 (−7.65–8.63)
FTO
rs9939609CodominantTotalTT23.88 (0.46)ref.0.65
TA24.53 (0.62)0.65 (−0.88–2.18)
AA23.84 (0.80)−0.03 (−1.91–1.85)
MaleTT24.20 (0.44)ref.0.71
TA24.19 (0.61)−0.02 (−1.52–1.49)
AA23.46 (0.85)−0.74 (−2.66–1.17)
FemaleTT22.69 (1.43)ref.0.41
TA25.85 (1.90)3.15 (−1.43–7.73)
AA24.78 (1.86)2.08 (−2.96–7.13)
BDNF
rs6265CodominantTotalCC24.30 (0.40)ref.0.55
CT23.59 (0.74)−0.71 (−2.25–0.83)
TT25.27 (2.04)0.96 (−2.85–4.78)
MaleCC24.05 (0.41)ref.0.74
CT23.88 (0.68)−0.17 (−1.71–1.37)
TT25.27 (2.04)1.21 (−2.14–4.57)
FemaleCC25.13 (1.07)ref.0.27
CT22.68 (2.24)−2.45 (−6.73–1.83)
TTNA-
BDNF
rs962369CodominantTotalTT24.65 (0.43)ref.0.20
TC23.30 (0.66)−1.35 (−2.81–0.12)
CC24.14 (1.04)−0.51 (−2.92–1.89)
MaleTT24.71 (0.46)ref.0.06
TC22.92 (0.57)−1.79 (−3.25–−0.33)
CC24.14 (1.04)−0.57 (−2.68–1.53)
FemaleTT24.45 (1.07)ref.0.96
TC24.34 (1.98)−0.11 (−4.19–3.97)
CCNA-
OverdominantMaleTT and CC24.61 (0.42)ref.0.02
TC22.92 (0.57)−1.69 (−3.09–−0.29)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bednarova, A.; Habalova, V.; Iannaccone, S.F.; Tkac, I.; Jarcuskova, D.; Krivosova, M.; Marcatili, M.; Hlavacova, N. Association of HTTLPR, BDNF, and FTO Genetic Variants with Completed Suicide in Slovakia. J. Pers. Med. 2023, 13, 501. https://doi.org/10.3390/jpm13030501

AMA Style

Bednarova A, Habalova V, Iannaccone SF, Tkac I, Jarcuskova D, Krivosova M, Marcatili M, Hlavacova N. Association of HTTLPR, BDNF, and FTO Genetic Variants with Completed Suicide in Slovakia. Journal of Personalized Medicine. 2023; 13(3):501. https://doi.org/10.3390/jpm13030501

Chicago/Turabian Style

Bednarova, Aneta, Viera Habalova, Silvia Farkasova Iannaccone, Ivan Tkac, Dominika Jarcuskova, Michaela Krivosova, Matteo Marcatili, and Natasa Hlavacova. 2023. "Association of HTTLPR, BDNF, and FTO Genetic Variants with Completed Suicide in Slovakia" Journal of Personalized Medicine 13, no. 3: 501. https://doi.org/10.3390/jpm13030501

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop